Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibilities for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CONCORD HEALTHCARE GROUP CO., LTD.
美中嘉和醫學技術發展集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

VOLUNTARY ANNOUNCEMENT
FORMATION OF STRATEGIC PARTNERSHIP

This announcement is made by the board of directors (the "**Board**") of Concord Healthcare Group Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Board is pleased to announce that the Company has entered into a strategic partnership with Hong Kong and Macau branches of AIA International Limited ("**AIA Hong Kong and Macau**") recently.

As part of the collaboration, the eligible insured members of AIA Hong Kong and Macau's designated group insurance can have access to more affordable designated cancer proton therapy and health screening packages at Guangzhou Concord Cancer Center (廣州泰和腫瘤醫院) one of the Group's flagship institutions. This partnership aligns with AIA Hong Kong and Macau's strategies in supporting and enhancing holistic employee wellbeing under the WorkWell with AIA programme. This partnership also represents a key step in the Company's strategic deployment in the health ecosystem and brings comprehensive and quality cancer and health-related services to the eligible insured members of AIA Hong Kong and Macau's designated group insurance.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Concord Healthcare Group Co., Ltd.
美中嘉和醫學技術發展集團股份有限公司
YANG Jianyu
Chairman and Executive Director

Beijing, the PRC, September 16, 2025

As at the date of this announcement, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.